Posted by jrbecker76 on August 19, 2014, at 10:56:07
In reply to Re: Ketamine pipeline » Willyee234, posted by phidippus on August 3, 2014, at 14:04:17
> not anytime soon. abuse potential is too high. that and clinical data isn't significant.
>
> EricI'm not sure what you're basing this conclusion on.
The data from ketamine-like compounds is actually quite compelling. I have been involved in a number of clinical trials, including intraveneous ketamine, Decoglurant (aka RO4995819, RG1578 - a mGlu2 antag) as well as GLYX-13 (a partial Glycine agonist). Although I was personally not a responder to these treatments, the trials as a whole have produced significant efficacy that are pushing them towards late-stage clinical trial development. On a related note, J&J's intranasal Esketamine as well as Cerecor's CERC-301 have both received the FDA's Fast-Track status.
poster:jrbecker76
thread:1069138
URL: http://www.dr-bob.org/babble/20140815/msgs/1070003.html